Bisphosphonates for breast cancer patients

Bookmark and Share
Published: 9 Feb 2010
Views: 10413
Prof Michael Gnant - Medical University of Vienna, Austria
Benefits of adding bisphosphonates to endrocrine therapy for breast cancer to potentially increase anti-tumour efficacy. Denosumab vs Zoledronate. Interviewed by an expert from the European Institute of Oncology at San Antonio Breast Cancer Symposium 2009.

Click on a link below to see Prof Gnant speaking about his research into the influence of zoledronic acid on breast cancer treatments:
Prof Gnant talks to ecancertv about the mature results of the ABCSG-12 trial at ASCO 2010.
Prof Gnant gives a presentation of his results at ESMO 33.